Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Suspended 1Recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Other hematologic neoplasm 1Myeloid 1

Conditions

Pancreatic Neoplasms 1Colorectal Neoplasms 1

Interventions

Fluorouracil 56Specimen Handling 51Oxaliplatin 49Leucovorin 46Magnetic Resonance Spectroscopy 45Bevacizumab 43Gemcitabine 39Irinotecan 30Cetuximab 27Nivolumab 25130-nm albumin-bound paclitaxel 25Cisplatin 24Biopsy 24pembrolizumab 22Paclitaxel 22Capecitabine 19atezolizumab 18durvalumab 14Taxes 14Folfox protocol 14Carboplatin 13X-Rays 12Radiotherapy 12Cyclophosphamide 12fludarabine 11dehydroftorafur 10Radiation 10Albumin-Bound Paclitaxel 10Surgical Procedures, Operative 9Immunoglobulin G 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
CA-4948 × Gastrointestinal × 30 days × Clear all
NCT06696768 2026-06-03

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
24 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05685602 2026-05-18

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡